| Title |
Cancer immunotherapy in patients with brain metastases
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, March 2018
|
| DOI | 10.1007/s00262-018-2146-8 |
| Pubmed ID | |
| Authors |
Salvatore Caponnetto, Arianna Draghi, Troels Holz Borch, Marianna Nuti, Enrico Cortesi, Inge Marie Svane, Marco Donia |
| Abstract |
The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 50% |
| Portugal | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 21% |
| Researcher | 9 | 16% |
| Other | 5 | 9% |
| Student > Master | 5 | 9% |
| Student > Bachelor | 4 | 7% |
| Other | 9 | 16% |
| Unknown | 13 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 19% |
| Immunology and Microbiology | 7 | 12% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Neuroscience | 3 | 5% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 9 | 16% |
| Unknown | 20 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2019.
All research outputs
#6,506,177
of 23,923,788 outputs
Outputs from Cancer Immunology, Immunotherapy
#895
of 2,897 outputs
Outputs of similar age
#111,766
of 335,502 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#10
of 31 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,897 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,502 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.